61 patents currently held
430 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Of the 430 now held by other companies, 240 name Bayer CropScience Aktiengesellschaft as their current owner, and 190 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
29
Ending by 2030
Dec 2026
Next term end
48
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2031 · Medium confidence
Also notable
Ends Apr 2030 · Medium confidence
Also notable
Ends Mar 2032 · High confidence
Also notable
Ends Jul 2030 · Medium confidence
Also notable
Ends Jan 2028 · High confidence
Also notable
Ends Aug 2031 · High confidence
Also notable
Ends Oct 2027 · Medium confidence
Also notable
Ends Jul 2030 · Medium confidence
Substituted 5-Fluoro-1H-PYRAZOLOPYRIDINES and Their Use
US 9,266,885
Cited by 26 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Anti-Mesothelin Immunoconjugates and Uses Therefor
US 10,781,263
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Branched 3-Phenylpropionic Acid Derivatives and Their Use
US 8,796,335
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Pharmaceutical Composition Containing a Tetrahydrofolic Acid
US 11,617,751
The most cited patent in this portfolio, cited by 52 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2030.
Medicaments Containing Vardenafil Hydrochloride Trihydrate
US 8,273,876
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Method for Detecting Pyrophosphate by Means of Bioluminescence Detection
US 8,969,045
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2031.
Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases
US 8,653,111
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
17-Hydroxy-17-Pentafluoroethyl-ESTRA-4,9(10)-DIEN-11-ARYL Derivatives, Method of Production Thereof and Use Thereof for the Treatment of Diseases
US 10,155,004
A family of 5 related applications built on the 2018 grant. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Dec 2027 · High confidence
Cited by 69 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Parker Intangibles LLC
Also notable
Ends May 2031 · High confidence
Cited by 78 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Adverio Pharma GmbH
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Nontoxic Polysiloxane Material for Producing Biologically Resorbable And/Or Bioactive Articles Containing Polysiloxane Material, Its Production and Use (US 9,051,204) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Jan 21, 2027The maintenance fee for Anti-Mesothelin Immunoconjugates and Uses Therefor (US 9,084,829) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Substituted 2,3-Dihydroimidazo[1,2-c]quinazoline Salts (US 10,383,876) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 2 fees due Mar 8 to 15, 2027 · next Mar 8
- 2 fees due Apr 8 to 20, 2027 · next Apr 8
- 1 fee due May 5, 2027The maintenance fee for Use of Alternan as Texturizing Agent in Foodstuffs and Cosmetics (US 10,463,606) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 2 fees due Jun 8 to 10, 2027 · next Jun 8
- 4 fees due Jul 5 to 26, 2027 · next Jul 5
- 1 fee due Aug 23, 2027The maintenance fee for Substituted 5-Fluoro-1H-PYRAZOLOPYRIDINES and Their Use (US 9,266,885) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Anti-Mesothelin Immunoconjugates and Uses Therefor (US 10,647,779) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 6 terms have ended since Aug 21, 2026
What they patent
The largest of its 48 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,463,666 | Pharmaceutical Composition Comprising Progestogens And/Or Estrogens and 5-Methyl-(6S)-TETRAHYDROFOLATE held by Bayer Intellectual Property GmbH and Merck & Cie In force · High confidence | In force | High confidence | |
| US 7,714,144 | Method for the Production of 5-Fluoro-1,3-Dialkyl-1H-PYRAZOL-4-Carbonyl Fluorides In force · High confidence | In force | High confidence | |
| US 8,324,412 | Method for Preparing 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-Oxoestra-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-Oxime (ASOPRISNIL) In force · High confidence | In force | High confidence | |
| US 8,653,111 | Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases In force · Medium confidence | In force | Medium confidence | |
| US 9,168,249 | Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases In force · Medium confidence | In force | Medium confidence | |
| US 7,932,278 | 2-Aminoethoxyacetic Acid Derivatives and Their Use In force · High confidence | In force | High confidence | |
| US 8,273,876 | Medicaments Containing Vardenafil Hydrochloride Trihydrate In force · High confidence | In force | High confidence | |
| US 8,153,616 | Combination Preparation for Oral Contraception and Oral Therapy of Dysfunctional Uterine Bleeding Containing Estradiol Valerate and Dienogest and Method of Using Same In force · Medium confidence | In force | Medium confidence | |
| US 9,051,204 | Nontoxic Polysiloxane Material for Producing Biologically Resorbable And/Or Bioactive Articles Containing Polysiloxane Material, Its Production and Use In force · High confidence | In force | High confidence | |
| US 9,862,940 | Silica Sol Material for Producing Bilogically Degradable And/Or Resorbable Silica Gel Materials, the Production and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 61: 430 patents in force now held by others · 1,301 patents ended · 4 applications pending · 628 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.